Vera Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Vera Therapeutics CEO'su Marshall Fordyce, May2016 tarihinde atandı, in görev süresi 8.5 yıldır. in toplam yıllık tazminatı $ 3.43M olup, şirket hissesi ve opsiyonları dahil olmak üzere 17.1% maaş ve 82.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.36% ine doğrudan sahiptir ve bu hisseler $ 11.07M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 4.1 yıldır.

Anahtar bilgiler

Marshall Fordyce

İcra Kurulu Başkanı

US$3.4m

Toplam tazminat

CEO maaş yüzdesi	17.1%
CEO görev süresi	8.5yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	4.1yrs

Son yönetim güncellemeleri

Recent updates

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Jan 19

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

Jan 07

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25

Vera Therapeutics soars 16% on three new favorable view from analysts

Jun 08

CEO Tazminat Analizi

Marshall Fordyce'un ücretlendirmesi Vera Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$134m
Jun 30 2024	n/a	n/a	-US$108m
Mar 31 2024	n/a	n/a	-US$94m
Dec 31 2023	US$3m	US$586k	-US$96m
Sep 30 2023	n/a	n/a	-US$103m
Jun 30 2023	n/a	n/a	-US$107m
Mar 31 2023	n/a	n/a	-US$102m
Dec 31 2022	US$4m	US$551k	-US$89m
Sep 30 2022	n/a	n/a	-US$73m
Jun 30 2022	n/a	n/a	-US$56m
Mar 31 2022	n/a	n/a	-US$45m
Dec 31 2021	US$1m	US$479k	-US$33m
Sep 30 2021	n/a	n/a	-US$59m
Jun 30 2021	n/a	n/a	-US$55m
Mar 31 2021	n/a	n/a	-US$56m
Dec 31 2020	US$3m	US$360k	-US$53m

Tazminat ve Piyasa: Marshall 'nin toplam tazminatı ($USD 3.43M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 6.54M ).

Tazminat ve Kazançlar: Marshall 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Marshall Fordyce (49 yo)

8.5yrs

Görev süresi

US$3,429,733

Tazminat

Dr. Marshall W. Fordyce, M.D. is Founder of Vera Therapeutics, Inc. and has been its President, Chief Executive Officer and Director since May 2016. From April 2011 to July 2016, Dr. Fordyce held a number...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Marshall Fordyce	Founder	8.5yrs	US$3.43m	0.36% $ 11.1m
Sean Grant	Chief Financial Officer	3.3yrs	US$1.76m	0.036% $ 1.1m
David Johnson	Chief Opearating Officer	less than a year	Veri yok	Veri yok
Joseph Young	Senior VP of Finance & Chief Accounting Officer	3.5yrs	Veri yok	0.031% $ 934.0k
Jason Carter	Chief Legal Officer	no data	Veri yok	Veri yok
Kelly Rauber	Senior Vice President of Human Resources	2.8yrs	Veri yok	Veri yok
Tom Doan	Senior Vice President of Development Operations	4.7yrs	Veri yok	Veri yok
Lauren Frenz	Chief Business Officer	7.3yrs	Veri yok	Veri yok
Julien Capers	Senior Vice President of Legal	no data	Veri yok	Veri yok
Neeraj Pakala	Senior VP and Head of Product Development & Manufacturing	1.9yrs	Veri yok	Veri yok
Kerry Cooper	Senior Vice President of Medical Affairs	1.5yrs	Veri yok	Veri yok
Robert Brenner	Chief Medical Officer	less than a year	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: VERA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Marshall Fordyce	Founder	8.5yrs	US$3.43m	0.36% $ 11.1m
Maha Katabi	Independent Director	4.1yrs	US$153.63k	0% $ 0
Michael Morrissey	Independent Chairman of the Board	2.5yrs	US$187.13k	0% $ 0
Patrick Gerald Enright	Independent Director	4.1yrs	US$155.63k	0% $ 0
Beth Seidenberg	Independent Director	8.4yrs	US$153.13k	0.21% $ 6.5m
Scott William Morrison	Independent Director	4.6yrs	US$160.63k	0% $ 0
Andrew Cheng	Independent Director	7.5yrs	US$154.63k	0.028% $ 844.9k
Christy Oliger	Director	less than a year	Veri yok	0.0047% $ 144.4k
Kimball Hall	Independent Director	2.9yrs	US$152.04k	0% $ 0

4.1yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VERA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).

Vera Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Vera Therapeutics, Inc. Appoints Jason S. Carter as Chief Legal Officer

Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Chief Financial Officer recently sold US$735k worth of stock

Recent updates

Vera Therapeutics, Inc. Appoints Jason S. Carter as Chief Legal Officer

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.000036 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Vera Therapeutics, Inc. Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN at the American Society of Nephrology Kidney Week 2024

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Vera Therapeutics, Inc. Announces Expanded Atacicept Development Program in Multiple Autoimmune Kidney Diseases

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Vera Therapeutics, Inc.(NasdaqGM:VERA) dropped from Russell 3000E Value Index

Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Price target increased by 17% to US$55.80

Chief Financial Officer recently sold US$735k worth of stock

Chief Financial Officer notifies of intention to sell stock

Vera Therapeutics, Inc., Annual General Meeting, May 15, 2024

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Price target increased by 36% to US$32.11

New minor risk - Share price stability

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Vera Therapeutics, Inc. Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b Origin Clinical Trial Ole in IgA Nephropathy

Vera Therapeutics, Inc. Announces Executive Changes

New minor risk - Share price stability

Price target increased by 12% to US$22.14

New major risk - Revenue and earnings growth

Price target increased by 16% to US$18.50

Price target increased by 10% to US$16.00

Price target decreased by 10% to US$14.50

New minor risk - Share price stability

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Price target decreased by 18% to US$15.67

Chief Financial Officer recently bought US$100k worth of stock

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Therapeutics, Inc. Hosting A Key Opinion Leader Webinar on Atacicept for the Treatment Iga Nephropathy (Igan)

Price target decreased to US$19.17

Vera Therapeutics, Inc. Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Chief Development Officer exercised options and sold US$148k worth of stock

Founder exercised options to buy US$1.1m worth of stock.

High number of new directors

Chief Development Officer exercised options and sold US$95k worth of stock

Founder exercised options and sold US$576k worth of stock

Chief Development Officer exercised options and sold US$186k worth of stock

Founder exercised options and sold US$622k worth of stock

Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove

Founder exercised options and sold US$354k worth of stock

Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17

Vera Therapeutics Completes Patient Enrollment in Phase 2B Origin Clinical Trial of Atacicept for the Treatment of Iga Nephropathy

Chief Financial Officer recently bought US$68k worth of stock

Vera Therapeutics, Inc. Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

High number of new directors

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

High number of new directors

Vera Therapeutics, Inc., Annual General Meeting, May 24, 2022

Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

High number of new directors

Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Vera Therapeutics soars 16% on three new favorable view from analysts